AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits.While RT-PCR diagnostic kits has provided fast and sensitive COVID-19 case confirmation, the technique suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To facilitate rapid screening and instant detection of SARS-CoV-2 infection, development of faster and convenient antibody and antigen-based…
New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment
Westbury, NY – Oct. 12, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).1
DILI contributes to the high failure rate of drug candidates in clinical…
Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.
The Spark Building was built to accommodate the companies scaling up to create a new wave of advanced cell and gene therapy treatments with the potential to cure cancer and other life-threatening diseases. A £1.2m Local Growth Fund investment from Hertfordshire Local Enterprise Partnership (LEP) has financed 50% of the 10,000 sq. ft. building, enabling the cell and gene cluster to continue to grow at…
Systematic direct cell conversion platform published in Cell Systems
Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells in culture and support conversion between cell types
EpiMOGRIFY co-developed and co-owned by Duke-NUS, Monash University and Mogrify
Company’s platforms support the development of scalable off-the-shelf cell therapies for diseases with a high unmet clinical need
Cambridge, UK 9th October 2020: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo…
The Department for International Trade (DIT) has classified Stevenage, Hertfordshire, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas investment into the county.
Stevenage is at the centre of the largest cluster of cell and gene therapy companies outside of the US. The growing cell and gene therapy campus in Stevenage is delivering over 1,000 jobs and is…
• TTP Ventus Disc Pump combined with Sensirion liquid flow sensor
• Together, technologies provide exceptional liquid flow control
• New system suitable for laboratory testing and product prototyping
Cambridge, UK, 07 October 2020: Micropump manufacturer TTP Ventus Ltd today announces its collaboration with Sensirion AG – a leading manufacturer of high-quality sensor solutions – on the design of a compact high-performance microfluidic driver. The system has been created to support laboratory prototyping and product development for a wide range of microfluidics applications, from laboratory…
The Biosphere, a specialist lab facility on Newcastle Helix, has welcomed yet another Newcastle University spin-out, who has developed and commercialised a prognostic test for early-stage skin cancer.
Formed in 2017, AMLo Biosciences’ first product (AMBLor) - a ground-breaking melanoma test will go to market in 2021. AMBLor will be launched in both the UK, USA and Australia and has the potential to save up to 2,000 lives every year as well as reassure thousands of others that their early stage skin cancer will not progress. This first-in class diagnostic identifies the metastatic…
Biohazards are understandably in the spotlight again, due to COVID-19. As a health and safety consultancy specialising in the scientific sector, Bishop Simon Ltd was asked by the Institution of Occupational Safety and Health Magazine to contribute to their article “ARE YOU PREPARED FOR THE NEXT BIOHAZARD” - https://www.ioshmagazine.com/2020/09/09/are-you-prepared-next-biohazard. The article focuses on health and safety practices that organisations are applying to meet the challenges of outbreaks. Our focus was on how organisations can positively influence the behaviour of their workforce in…
Below you'll find a list of events and conferences where One Nucleus will be in attendance. Feel free to reach out during these conferences to speak to our BD team.
We can offer a discount on registration, to our members, to many of the below. Get in touch here for discount codes.
8 October - Optimum Communications Annual Healthcare Investor Conference
14-15 October - UK Bioscience Forum
15 October - MedTech Integrates
26-27 October - SynbiTECH
27-30 October - MedTech Innovation Forum
26-29 October - BIO-Europe
09-12 November - …